Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer

被引：0
|
作者：
Dan Lu
Chunze Li
Matthew Riggs
Daniel Polhamus
Jonathan French
Priya Agarwal
Shang-Chiung Chen
Shweta Vadhavkar
Monika Patre
Alexander Strasak
Angelica Quartino
Jin Yan Jin
Sandhya Girish
机构：
[1] Genentech,Department of Clinical Pharmacology
[2] Inc.,undefined
[3] Metrum Research Group,undefined
[4] F. Hoffmann-La Roche Ltd.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 84卷
关键词：
Trastuzumab emtansine (T-DM1); HER2; Pharmacokinetics; Previously untreated metastatic breast cancer; MARIANNE;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：175 / 185
页数：10
相关论文
共 50 条
  • [41] Ado-trastuzumab emtansine (T-DM1) in HER2+advanced breast cancer patients: does pretreatment with pertuzumab matter?
    Fabi, Alessandra
    Giannarelli, Diana
    Moscetti, Luca
    Santini, Daniele
    Zambelli, Alberto
    De laurentiis, Michelino
    Caruso, Michele
    Generali, Daniele
    Valle, Enrichetta
    Leonardi, Vita
    Cannita, Katia
    Arpino, Grazia
    Filippelli, Gianfranco
    Ferretti, Gianluigi
    Giampaglia, Marianna
    Montemurro, Filippo
    Nistico, Cecilia
    Gasparro, Simona
    Cognetti, Francesco
    FUTURE ONCOLOGY, 2017, 13 (30) : 2791 - 2797
  • [42] Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer
    Burris, Howard A., III
    Tibbitts, Jay
    Holden, Scott N.
    Sliwkowski, Mark X.
    Phillips, Gail D. Lewis
    CLINICAL BREAST CANCER, 2011, 11 (05) : 275 - 282
  • [43] Pertuzumab and T-DM1: New perspectives in the treatment of HER2-positive breast cancer
    Guiu, S.
    Fumoleau, P.
    ONCOLOGIE, 2015, 17 (5-6) : 263 - 270
  • [44] The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer
    Delgado, J.
    Vleminckx, C.
    Sarac, S.
    Sosa, A.
    Bergh, J.
    Giuliani, R.
    Enzmann, H.
    Pignatti, F.
    ESMO OPEN, 2021, 6 (02)
  • [45] Results from a phase Ib study of trastuzumab emtansine (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab.
    Modi, Shanu
    Elias, Anthony D.
    LoRusso, Patricia
    Samant, Meghna
    Guardino, Ellie
    Althaus, Betsy
    Krop, Ian E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
    Michel, Laura L.
    Hartkopf, Andreas D.
    Fasching, Peter A.
    Kolberg, Hans-Christian
    Hadji, Peyman
    Tesch, Hans
    Haberle, Lothar
    Ettl, Johannes
    Luftner, Diana
    Wallwiener, Markus
    Mueller, Volkmar
    Beckmann, Matthias W.
    Belleville, Erik
    Volz, Bernhard
    Huebner, Hanna
    Wimberger, Pauline
    Hielscher, Carsten
    Mundhenke, Christoph
    Kurbacher, Christian
    Wuerstlein, Rachel
    Untch, Michael
    Overkamp, Friedrich
    Huober, Jens
    Janni, Wolfgang
    Taran, Florin-Andrei
    Lux, Michael P.
    Wallwiener, Diethelm
    Brucker, Sara Y.
    Schneeweiss, Andreas
    Fehm, Tanja N.
    CANCERS, 2020, 12 (10) : 1 - 15
  • [47] TRASTUZUMAB EMTANSINE FOR THE TREATMENT OF HER2-POSITIVE METASTATIC BREAST CANCER
    Haddley, K.
    DRUGS OF TODAY, 2013, 49 (11) : 701 - 715
  • [48] Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
    Matteo Allegretti
    Alessandra Fabi
    Elena Giordani
    Cristiana Ercolani
    Paolo Romania
    Cecilia Nisticò
    Simona Gasparro
    Vittoria Barberi
    Maria Ciolina
    Edoardo Pescarmona
    Diana Giannarelli
    Gennaro Ciliberto
    Francesco Cognetti
    Patrizio Giacomini
    Molecular Cancer, 20
  • [49] Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
    Allegretti, Matteo
    Fabi, Alessandra
    Giordani, Elena
    Ercolani, Cristiana
    Romania, Paolo
    Nistico, Cecilia
    Gasparro, Simona
    Barberi, Vittoria
    Ciolina, Maria
    Pescarmona, Edoardo
    Giannarelli, Diana
    Ciliberto, Gennaro
    Cognetti, Francesco
    Giacomini, Patrizio
    MOLECULAR CANCER, 2021, 20 (01)
  • [50] Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1
    Montemurro, Filippo
    Ellis, Paul
    Anton, Antonio
    Wuerstlein, Rachel
    Delaloge, Suzette
    Bonneterre, Jacques
    Quenel-Tueux, Nathalie
    Linn, Sabine C.
    Irahara, Natsumi
    Donica, Margarita
    Lindegger, Nicolas
    Barrios, Carlos H.
    EUROPEAN JOURNAL OF CANCER, 2019, 109 : 92 - 102
12345